Indications
Brolucizumab is a human vascular endothelial growth factor (VEGF) inhibitor. It is used to treat neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Brolucizumab is a human VEGF inhibitor. It binds to the three major isoforms of VEGF-A (VEGF 110, VEGF 121 and VEGF 165), and this stops VEGF-A from interacting with the receptors VEGFR-1 and VEGFR-2. With VEGF-A blocked, brolucizumab suppresses endothelial cell proliferation, neovascularization and vascular permeability.
Blood and fluid can leak from choroidal neovascularization (CNV), and this may cause retinal thickening or edema. On optical coherence tomography (OCT), increased retinal thickness and a build-up of intraretinal fluid (IRF) or subretinal fluid (SRF) are linked with nAMD and DME. Reductions in central retinal subfield thickness (CST) were seen across all treatment arms.
Pregnancy & Breastfeeding
There are no adequate and well-controlled studies of BEOVU use in pregnant women. In an animal reproduction study, pregnant monkeys were given brolucizumab by injection into one eye once every 4 weeks, from organogenesis to birth. At 10-fold the maximum recommended human dose (MRHD) on a mg/kg basis, this caused fetal loss and a structural abnormality (bilateral absent metatarsal) in the offspring.
Nobody knows whether brolucizumab passes into human milk, what it does to a breastfed infant, or whether it affects milk production or excretion. Many drugs do transfer into human milk, and a breastfed child could absorb the drug and have adverse reactions. For that reason, breastfeeding is not recommended during treatment with Brolucizumab, or for at least one month after the last dose when treatment is stopped.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.